Kyowa Hakko Kirin Co., Limited

Kyowa Kirin Co., Ltd.

Arca Biopharma, Inc.

Makoto Kakitani

Kazuma Tomizuka

Walter D Funk

Tom Y Tang

Takeshi Oshima

Eun Ju Park

Kengo Yamawaki

Mikio Yagi

Bryan J Boyle

Kazuma Tmizuka

Takeshi Pharmaceutical Research Lab Oshima

This invention relates to a pharmaceutical composition for treatment of a bone disease comprising, as an active ingredient, a protein comprising an extracellular cysteine-rich domain, which is from the Frizzled receptor selected from the group consisting of mammalian animal-derived Frizzled 1, Frizzled 2, and Frizzled 7 and has activity of increasing bone mass, bone density, and/or bone strength, or a mutant of such domain having sequence identity of 85% or higher to the amino acid sequence of the domain and having activity of increasing bone mass, bone density, and/or bone strength, or a vector comprising a nucleic acid encoding the protein.

Pharmaceutical composition for treating bone diseases which comprises protein comprising Frizzled 1, Frizzled 2 or Frizzled 7 extracellular cysteine-rich domain

Pharmaceutical composition for treating bone diseases which comprises protein comprising Frizzled1, Frizzled2 or Frizzled7 extracellular cysteine-rich domain

The present invention provides a protein comprising a truncated form of an extracellular region protein of Frizzled 2, which has higher secretion activity than that of a known protein comprising an extralellular cysteine-rich domain of Frizzled 2 in a production cell and bone mass-increasing activity higher than or equal to that of the known protein, or DNA encoding said protein.

Protein comprising truncated form of extracellular region protein of Frizzled 2, and pharmaceutical composition for treating bone diseases which comprises said protein

The invention relates to pharmaceutical compositions comprising gastrointestinal proliferative factor (GIPF) polynucleotides and polypeptides. The invention further relates to the therapeutic use of GIPF to prevent or treat conditions or disorders associated with the degeneration of the epithelial mucosa.

Method of stimulating epithelial cell proliferation by administration of gastrointestinal proliferative factor

Growing community of inventors

Tokyo, Japan

Makoto Kakitani